Document is current
Any future updates will be listed below
-
Authors
Romera, Irene Cristina https://orcid.org/0000-0002-1345-9799
Redondo-Antón, Jennifer https://orcid.org/0000-0003-2661-5866
Rubio-de Santos, Miriam https://orcid.org/0000-0001-7393-6334
Díaz-Cerezo, Silvia https://orcid.org/0000-0001-6351-818X
Artime, Esther https://orcid.org/0000-0003-4294-6462
Rafels-Ybern, Albert https://orcid.org/0000-0002-1864-6155
Ortega, Emilio https://orcid.org/0000-0002-2217-8905
Conget, Ignacio https://orcid.org/0000-0002-5532-5449
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 5 November 2024
Accepted: 11 March 2025
First Online: 27 March 2025
Declarations
:
: Irene Cristina Romera, Jennifer Redondo-Antón, Miriam Rubio-de Santos, Silvia Díaz-Cerezo, and Esther Artime are employees and minor shareholders of Lilly and Company. Albert Rafels-Ybern is an employee of IQVIA information. Emilio Ortega declares personal fees (consulting and lectures) and/or non-financial support from Akcea, Amgen, AstraZeneca, Daiichi-Sankyo, GlaxoSmithKline, Lilly/Boehringer-Lilly, MSD, NovoNordisk, Pfizer, and Sanofi. Ignacio Conget reports honoraria for speaking from Medtronic, Eli Lilly, Novo Nordisk, Sanofi-Aventis, Astra Zeneca, Boehringer Ingelheim, and Merck Sharp and Dohme; and consulting fees from Medtronic, Eli Lilly, Novo Nordisk, and Sanofi-Aventis.
: The REPRESENT study and this post hoc analysis were approved by the accredited Clinical Research Ethics Committees of the Hospital Clínic de Barcelona before study initiation (Reg. HCB/2020/0663). The study was also conducted according to Good Clinical Practice guidelines (International Conference of Harmonization) and the Declaration of Helsinki. As this study was based on an existing database from the REPRESENT study, no informed consent was required to participate in the study. The database granted permission for this post hoc study.
